Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Major Depressive Disorder: full-pipeline trial registry
109 of 283 indexed Major Depressive Disorder trials are currently recruiting.
Corpus placement: #33 of 28,707 conditions by registered trial count.
283 US clinical trials · 109 currently recruiting · #33 of 28,707 conditions by registered trial count
Major Depressive Disorder: 283 US clinical trials tracked, 109 recruiting.
Major Depressive Disorder is the subject of 283 registered US clinical trials on ClinicalTrials.gov, 109 of them currently open to new participants. 74 are in Phase 3-4 (later-stage) and 81 in Phase 1-2 (earlier-stage). The most active sponsor is Massachusetts General Hospital, running 19 of these trials.
Enrollment posture brief
Registry condition major-depressive-disorder
OPEN 109 | RECR 39% | LATE 74 | EARLY 81 | RANK #33 | SPON 19
Volume-matched condition peers
Nearest open-share peer: Anaplastic Oligodendroglioma (38% recruiting · 13 trials)
Major Depressive Disorder lists 109 open slots (39% of 283 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Major Depressive Disorder on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Major Depressive Disorder recruits in line with its size-band peers.
109 of 283 indexed trials (38.5%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Major Depressive Disorder trials is spread across many organizations.
Massachusetts General Hospital accounts for 19 of 283 trials (6.7%). 118 distinct sponsors appear on at least one study for this condition label.
-
Typical Major Depressive Disorder enrolment sits around 81 participants.
Median target enrolment is 81 among the 283 trials that report a genuine target (sentinel values excluded). 145 of those (51.2%) plan for fewer than 100 participants.
-
Major Depressive Disorder research is mostly interventional.
258 interventional and 25 observational studies make up this index (91.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
283 total, page 3 of 6
Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)
NYU Langone Health
NCT05757791
Neurobehavioral Therapy For Epilepsy And Major Depressive Disorder
The University of Texas Health Science Center, Houston
NCT06695767
Acceptability and Feasibility of Transcranial Magnetic Stimulation (TMS) for Depression in Multiple Sclerosis
University of Utah
NCT06329414
DBS for Depression
Baylor College of Medicine
NCT03437928
Closed-Loop Deep Brain Stimulation for Major Depression
Andrew Krystal
NCT04004169
Invasive Decoding and Stimulation of Altered Reward Computations in Depression Patients
Icahn School of Medicine at Mount Sinai
NCT05239780
Pilot Study of Personalized Aperiodic Transcranial Alternating Current Stimulation in Antenatal Depression (PandA-tACS)
University of North Carolina, Chapel Hill
NCT06979154
DBS for TRD With the Medtronic Percept PC
Helen Mayberg, MD
NCT05773755
Behavioral and Neuronal Correlates of Human Mood States
Stanford University
NCT06159595
Appalachian Mind Health Initiative
University of South Florida
NCT04120285
Open Label Optimization Study
Magnus Medical
NCT05819021
Self-guided Treatment for Depression
Big Health
NCT06028984
Using mHealth to Improve Adherence and Reduce Blood Pressure in Individuals With Hypertension and Mood Disorders
Case Western Reserve University
NCT04675593
Fisher Wallace Neurostimulation & Depression Study
ProofPilot
NCT04541563
A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge)
Definium Therapeutics US
NCT06941844
Unobtrusive Monitoring of Affective Symptoms and Cognition Using Keyboard Dynamics (UnMASCK)
University of Illinois at Chicago
NCT04358900
Imaging mGluR5 and Synaptic Density in Psychiatric Disorders
Yale University
NCT03898297
A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder
COMPASS Pathways
NCT05733546
Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder
Johns Hopkins University
NCT04620759
Predictors of Cognitive Outcomes in Geriatric Depression
David Steffens
NCT05273996
Impact of Transcutaneous Vagal Nerve Stimulation on Stress Response in Major Depression
Massachusetts General Hospital
NCT04448327
Opiate Suicide Study in Patients With Major Depression
Stanford University
NCT04116528
Mechanism of Action of Transcranial Magnetic Stimulation
Massachusetts General Hospital
NCT04278521
Individualized (fMRI-guided) TMS Treatment for Depression
University of Pennsylvania
NCT06266390
The Effect of Celecoxib on Neuroinflammation in MDD
Stony Brook University
NCT04814355
Psilocybin for Treatment-Resistant Depression
University of Colorado, Denver
NCT06230757
Tracking Brain Biomarkers and Renormalization Associated With Antidepressant Transcranial Magnetic Stimulation Therapy
Medical University of South Carolina
NCT06043401
Deep Brain Stimulation for Treatment Resistant Depression
Emory University
NCT00367003
Effects of Intravenous (IV) Citalopram Hydrochloride During Transcranial Magnetic Stimulation in Major Depressive Disorder (MDD)
University of California, Los Angeles
NCT04846829
Fixed Order, Open-Label, Dose-Escalation Study of DMT in Humans
Yale University
NCT04711915
EMA-Guided Maintenance TMS for Depression
Butler Hospital
NCT06145594
Individualized Targeting and Neuromodulation of Late-Life Depression
University of New Mexi
NCT04543773
Ketamine-Assisted Mindfulness-Based Cognitive Therapy for Depression: A Pilot Study
Ohio State University
NCT05950711
Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive Disorder
Yale University
NCT03554174
Ketamine Associated ACC GABA and Glutamate Change and Depression Remission:
Mayo Clinic
NCT03573349
Deep Brain Stimulation (DBS) Therapy for Treatment Resistant Depression
The University of Texas Health Science Center, Houston
NCT02046330
Testing a Transdiagnostic TMS Treatment Target
Brigham and Women's Hospital
NCT06282146
DBS for TRD With the Medtronic Summit RC+S
Helen Mayberg, MD
NCT04106466
Transcranial Electric Stimulation Therapy (TEST) for Treatment Resistant Depression (TRD)
National Institute of Mental Health (NIMH)
NCT05172271
A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Study of CERC-301 in the Adjunctive Treatment of Subjects With Severe Depression and Recent Active Suicidal Ideation Despite Antidepressant Treatment
Avalo Therapeutics
NCT01941043
A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder
Otsuka Pharmaceutical Development & Commercialization
NCT03538691
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Shire
NCT01436162
Escitalopram in Adult Patients With Major Depressive Disorder
Forest Laboratories
NCT00668525
Open-Label Safety Study of AXS-05 in Subjects With Depression
Axsome Therapeutics
NCT04039022
Safety Study of F2695 SR in Major Depressive Disorder
Forest Laboratories
NCT01034267
An Open-label Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Intra-Cellular Therapies
NCT05061719
Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder
Otsuka Pharmaceutical Development & Commercialization
NCT01052077
The Objective of This Study is to Evaluate the Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone
AbbVie
NCT03739203
Optimizing Outcomes of Treatment-Resistant Depression in Older Adults
Washington University School of Medicine
NCT02960763
Relapse-Prevention Study With Levomilnacipran ER (F2695 SR) in Patients With Major Depressive Disorder
Forest Laboratories
NCT01085812
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 24 |
| Phase 2 | 57 |
| Phase 3 | 45 |
| Phase 4 | 29 |
Top Sponsors
Named interventions
Most-linked intervention names on Major Depressive Disorder records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Major Depressive Disorder trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Major Depressive Disorder page
283 registered trials, 109 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 109 Major Depressive Disorder trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Massachusetts General Hospital sponsors the most Major Depressive Disorder trials on record, review their full trial history before evaluating a specific study. See Massachusetts General Hospital's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Major Depressive Disorder condition card totals 283 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.